“…Likewise, other companies have also pursued dual SERT and NET inhibitors and 5-HT 1A receptor agonists (Hatzenbuhler et al, 2006(Hatzenbuhler et al, , 2008. Other multiple target strategies for development of monoamine transporters inhibitors with additional activity as antidepressants (Millan, 2006(Millan, , 2009 include combined NRI activity and 5-HT 2A receptor antagonism (Heffernan et al, 2008), SSRI activity and neurokinin 1 receptor antagonists (Ryckmans et al, 2002a,b) or histamine H 3 receptor antagonist (Barbier et al, 2007). However, so far no data from clinical trials have been reported for such compounds.…”